Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials
Venkatraman N. et al, (2025), The Lancet Microbe, 100868 - 100868
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.
Venkatraman N. et al, (2025), The Lancet. Microbe
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children.
Natama HM. et al, (2024), The Lancet. Infectious diseases
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial
Silk SE. et al, (2024), The Lancet Infectious Diseases, 24, 1105 - 1117
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
Datoo MS. et al, (2024), The Lancet, 403, 533 - 544
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial
Datoo MS. et al, (2022), The Lancet Infectious Diseases, 22, 1728 - 1736
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
Datoo MS. et al, (2021), The Lancet, 397, 1809 - 1818
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
Folegatti PM. et al, (2021), Vaccines, 9, 262 - 262
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
Folegatti PM. et al, (2020), The Lancet. Infectious diseases, 20, 816 - 826
Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
Folegatti PM. et al, (2019), Vaccines, 7, 40 - 40
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal
Venkatraman N. et al, (2019), The Journal of Infectious Diseases, 219, 1187 - 1197
Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line
Folegatti PM. et al, (2019), Vaccines, 7, 33 - 33
First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
Tiono AB. et al, (2018), PLOS ONE, 13, e0208328 - e0208328
Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP
Bliss CM. et al, (2018), Scientific Reports, 8
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP
Rampling T. et al, (2018), npj Vaccines, 3
Prime and target immunization protects against liver-stage malaria in mice
Gola A. et al, (2018), Science Translational Medicine, 10, eaap9128 - eaap9128
Corrigendum to “Heterologous Two-dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-lasting Cellular Immunity to Influenza Virus A in Healthy Adults” [EBioMedicine 29 (2018) 146–154]
Coughlan L. et al, (2018), EBioMedicine, 31, 321 - 321
Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults
Coughlan L. et al, (2018), EBioMedicine, 29, 146 - 154
"PRIME-TARGET" IMMUNIZATION WITH VIRAL VECTORS FOR ENHANCED EFFICACY OF LIVER-STAGE MALARIA VACCINES
Ewer K. et al, (2018), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 99, 585 - 585
Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial
Mensah VA. et al, (2017), Frontiers in Immunology, 8